April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
• Bedford discontinued lorazepam in May, 2011 to concentrate on the manufacturing of other<br />
products.<br />
• West-Ward acquired Baxter’s lorazepam injection products in May, 2011. The company cannot<br />
provide a reason for the shortage.<br />
• Hospira states lorazepam vials are on shortage due to increased demand. The 1 mL iSecure<br />
syringes were discontinued in September 2011<br />
• Akorn has increased production to help meet demand.<br />
Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=747<br />
Source: www.ashp.org<br />
Echothiophate Powder for Ophthalmic Solution<br />
March 30, <strong>2012</strong><br />
Products Affected - Description<br />
Phospholine Iodide 0.125%, Pfizer<br />
5 mL bottle (NDC 00046-1065-05)<br />
Reason for the Shortage<br />
• Pfizer (formerly Wyeth) states Phospholine Iodide is in short supply due to a raw material<br />
shortage.<br />
Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=85<br />
Source: www.ashp.org<br />
Ceftazidime Injection<br />
March 30, <strong>2012</strong><br />
Products Affected - Description<br />
Ceftazidime vials<br />
Ceftazidime injection, Pfizer<br />
500 mg vials (NDC 00069-0013-01) - discontinued<br />
1 gm vials (NDC 00069-0011-01) - discontinued<br />
2 gm vials (NDC 00069-0012-01) - discontinued<br />
6 gm vials (NDC 00069-0014-01) - discontinued<br />
Ceftazidime injection, Sagent<br />
1 gm vials, packages of 25 (NDC 25021-0127-20)<br />
2 gm vials, packages of 10 (NDC 25021-0128-50)<br />
6 gm vials, packages of 6 (NDC 25021-0129-99)<br />
Ceftazidime injection, West-Ward<br />
1 gm vials, packages of 25 (NDC 10019-0691-02) - discontinued<br />
2 gm vials, packages of 10 (NDC 10019-0692-03) - discontinued<br />
6 gm vials, packages 6 (NDC 10019-0693-04) - discontinued<br />
Tazicef injection, Hospira<br />
1 gm ADD-Vantage vials, packages of 25 (NDC 00409-5092-16)<br />
1 gm Novaplus ADD-Vantage vials, packages of 25 (NDC 00409-5092-52)<br />
2 gm ADD-Vantage vials, packages of 10 (NDC 00409-5093-11)<br />
2 gm Novaplus ADD-Vantage vials, packages of 10 (NDC 00409-5093-51)<br />
Reason for the Shortage<br />
• Pfizer discontinued all of its ceftazidime injection products in late-November, 2011.<br />
• West-Ward discontinued all of its ceftazidime injection products in January <strong>2012</strong>.<br />
• Hospira has ceftazidime on shortage due to manufacturing delays.<br />
• Sagent was not able to provide a reason for the shortage.<br />
78
Change language